Marketing: Page 2
-
Lilly launches online service for home delivery of weight loss drug
The new program, dubbed LillyDirect, will help patients connect with telehealth providers and deliver medicines like the company’s obesity drug Zepbound.
By Ned Pagliarulo • Jan. 4, 2024 -
Sponsored by Alexander Group
Profitable growth is on the horizon
A return to profitable growth is on the horizon—organizations that take advantage of the following key trends can thrive in 2024 and beyond.
Dec. 11, 2023 -
Trendline
Commercialization
New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.
By BioPharma Dive staff -
CVS overhauls how its retail pharmacies charge for prescription drugs
Under the new model, CVS’ pharmacy network will price drugs based on the amount the company paid for them, plus a defined markup and additional pharmacist fee.
By Rebecca Pifer • Dec. 5, 2023 -
Obesity drugs
European regulators want to know more about the risks of GLP-1 drugs
The EMA's safety committee has more questions for makers of the in-demand therapies as it reviews whether the drugs are linked to the risk of suicidal thoughts.
By Jacob Bell • Dec. 1, 2023 -
Cigna, Humana in talks to merge: WSJ
The merger would have major effects for the makeup of the U.S. health insurance industry, and would almost certainly face a regulatory challenge.
By Rebecca Pifer • Nov. 29, 2023 -
Medtronic CEO downplays impact of obesity drugs on procedures, devices
Surging demand for GLP-1 agonists has put medtech firms like Medtronic under pressure, even as they argue the hit to their businesses will be minimal.
By Ricky Zipp • Nov. 21, 2023 -
Bristol Myers faces FDA delay on cancer cell therapy decision
The regulator plans to convene an advisory panel to discuss an expanded indication for Abecma, presenting another hurdle for Bristol Myers and partner 2seventy bio.
By Ned Pagliarulo • Nov. 20, 2023 -
New AMA policies target GLP-1 coverage, corporate medicine
The lobbying group urged broader health insurance coverage for treating obesity, including with GLP-1 agonists like Wegovy.
By Susanna Vogel • Nov. 14, 2023 -
Obesity drugs
Wegovy study details revive debate over GLP-1 impact on devices
Shares in several heart device makers, which have been battered over the perceived impact of obesity medicines, rose this week following AHA data on Novo’s therapy.
By Susan Kelly • Nov. 13, 2023 -
Biogen, Sage set price of postpartum depression pill at $15,900
The price is below what some analysts had predicted and significantly less than $34,000 Sage initially set for its earlier postpartum infusion, Zulresso.
By Ned Pagliarulo • Nov. 7, 2023 -
Sponsored by Viatris
Transforming MS care to meet patient needs
Developing holistic treatment approaches that address patient needs today and in the future.
By Abhijit Barve, MD, PhD, MBA, Chief Medical Officer, Viatris • Nov. 6, 2023 -
Obesity drugs
Novo, Lilly buoyed by fast-growing GLP-1 drug sales
The rival companies reported strong quarterly sales growth for their latest products, which could face off as weight loss treatments next year.
By Jonathan Gardner • Nov. 2, 2023 -
Obesity drugs
The obesity drug effect: What medical device executives are saying
Stock selloffs across the medical device sector have erased hundreds of billions of dollars in market value. But medtech executives argue GLP-1 drug demand will complement, not cannibalize, their sales.
By Susan Kelly • Nov. 2, 2023 -
RSV vaccines
GSK outpaces Pfizer in RSV vaccine market
Sales of GSK’s new RSV shot Arexvy were more than double what Pfizer reported for its rival product, suggesting substantial demand this fall.
By Kristin Jensen • Nov. 1, 2023 -
Sponsored by Veeva
5 things to look for in a marketing analytics partner
Effective marketing measurement requires objectivity, connected data, transparency, a track record of innovation and a proven ability to execute.
Oct. 23, 2023 -
Roche eye drug sales grow as Regeneron plays catch-up
The Swiss pharma reported expanding U.S. market share for its new AMD drug Vabysmo as Regeneron tries to rebound from a now-resolved delay for its high-dose Eylea.
By Jonathan Gardner • Oct. 19, 2023 -
Keytruda gains first approval for pre- and post-surgery use in lung cancer
The Merck drug leads competitors Opdivo and Imfinzi into a new immunotherapy setting, which aims to improve outcomes following the surgical removal of tumors.
By Jonathan Gardner • Oct. 17, 2023 -
Pfizer wins FDA approval for its $7B colitis drug
Acquired with the buyout of Arena Pharmaceuticals, Velsipity enters a competitive market for ulcerative colitis pills.
By Jonathan Gardner • Oct. 13, 2023 -
ALS drug development
Amylyx’s ALS drug knocked back again in Europe
Following a re-examination, the EMA again concluded that Albrioza — known as Relyvrio in the U.S. — should not be cleared for the European market.
By Jacob Bell • Oct. 13, 2023 -
Obesity drugs
GLP-1 drug demand leaves employers in a bind over coverage
Employers face a difficult decision over whether to cover the popular weight loss therapies, which cost between $900 and $1,400 for a typical month’s supply at list price.
By Rebecca Pifer • Oct. 13, 2023 -
Apellis sales numbers show steady demand for new eye drug, despite safety worries
The company says Syfovre prescriptions accelerated again in August after a rocky summer of side effect probes.
By Kristin Jensen • Oct. 5, 2023 -
Sponsored by Cognizant
Using AI to create an end-to-end customer experience in pharma
Silos abound in the pharma world, especially when it comes to customer care and call center support. Using AI can change everything, though. Here’s how.
Oct. 2, 2023 -
New Alzheimer's drugs
Eisai’s Alzheimer’s drug Leqembi approved in Japan
Eisai and Biogen’s anti-amyloid drug is still undergoing regulatory reviews in the EU, U.K. and elsewhere.
By Ned Pagliarulo • Sept. 25, 2023 -
New RSV vaccines can be powerful tools, but rollout poses test
Public health officials, as well as drugmakers, are trying to raise awareness of RSV among older adults at risk, and convince them to get an additional respiratory shot alongside those for COVID-19 and flu.
By Delilah Alvarado • Sept. 18, 2023 -
FDA approves GSK’s new bone cancer drug, helping validate a billion-dollar bet
The drug, known scientifically as momelotinib, is now cleared to treat myelofibrosis and will compete against rival medicines sold by Incyte and Bristol Myers Squibb.
By Jacob Bell • Sept. 18, 2023